FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa

BALERNA, Switzerland, Dec. 4, 2019 /PRNewswire/ -- APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-nam...